State of the Art Pediatrics: Sleep Medicine and Pediatric Down Syndrome - Clinical Insights for Pediatricians

Down syndrome (DS), or trisomy 21, is the most common chromosomal condition, affecting approximately 1 in 700 live births. Children with DS face unique health challenges, and sleep disorders are among the most prevalent and impactful. Sleep plays a critical role in neurodevelopment, behavior and overall health, making its management essential in this population. This article will review epidemiology, pathophysiology, clinical implications and management strategies for sleep disorders in pediatric DS. 

Prevalence and Types of Sleep Disorders in Down Syndrome 

Sleep disturbances are highly prevalent in children with DS, with obstructive sleep apnea (OSA) being the most common disorder. Studies estimate that 30% to 80% of children with DS have OSA, compared to 2%–6% of the general pediatric population. ¹  Other sleep issues include insomnia, behavioral sleep difficulties and sleep-related hypoventilation.
 
OSA in DS is primarily due to anatomical factors (craniofacial anomalies such as midface hypoplasia, macroglossia, adenotonsillar hypertrophy) and is complicated by physiological factors such as hypotonia and comorbidities of obesity, hypothyroidism and gastroesophageal reflux. These factors contribute to airway obstruction during sleep, resulting in intermittent hypoxemia, fragmented sleep and increased cardiovascular strain. 

Clinical Presentation and Consequences 

Insomnia and behavioral sleep problems are common, often linked to anxiety, sensory sensitivities and poor sleep hygiene. These issues exacerbate daytime behavioral challenges and parental stress. 

Symptoms of OSA in DS include loud snoring, pauses in breathing, restless sleep, mouth breathing and daytime irritability or fatigue. However, many children with DS and OSA are asymptomatic, making routine screening critical. Untreated OSA can lead to cognitive and behavioral impairments, poor language development and, more seriously, increased risk of pulmonary hypertension and heart disease. 

Sleep-related hypoventilation can be subtle, and diagnosis requires a high index of suspicion. The only symptom that may be present is an early morning headache, which can be difficult to identify. Sleep-related hypoventilation may be present without significant nocturnal hypoxemia.

Screening and Diagnosis 

The American Academy of Pediatrics recommends polysomnography (PSG) by age 4 years for all children with DS, regardless of symptoms.²  PSG remains the gold standard for diagnosing OSA and other sleep disorders. Recent studies show that OSA severity correlates with age and tonsillar hypertrophy, with adolescents having the highest prevalence of severe OSA.³ 
 
Emerging research supports earlier screening in infants with DS who exhibit feeding difficulties, airway anomalies or pulmonary hypertension.⁴ Home sleep apnea testing is being explored as an alternative for families facing barriers to in-lab studies. 

Management Strategies 

1. Insomnia and Behavioral Sleep Problems 
   - Behavioral interventions: Establishing consistent bedtime routines, minimizing screen time and addressing sensory needs. 
   - Pharmacologic options: Medications such as trazodone, clonidine and doxepin may be considered for refractory cases under specialist guidance. 
2. Obstructive Sleep Apnea 
   - First-line treatment: Adenotonsillectomy, which is generally safe in DS patients when performed with appropriate perioperative care.³
   - Residual OSA: Common after surgery; continuous positive airway pressure (CPAP) therapy is recommended but often poorly tolerated due to sensory sensitivities. 
   - Innovative therapies: Hypoglossal nerve stimulation (HGNS), such as Inspire®, has emerged as an option for adolescents with DS who fail CPAP. ⁵  This device is implanted by ENT in the upper chest and provides stimulation of the tongue with inspiration. The device is controlled by a remote and managed by sleep medicine specialists. U.S. Food and Drug Administration approval now includes patients as young as 13 years, and the therapy is being tested in younger children. 
3. Multidisciplinary Care 
   - Management often requires collaboration among pediatricians, sleep specialists, ENT and behavioral health providers. Addressing comorbidities such as hypothyroidism and obesity is essential for optimizing outcomes. 

Emerging Research and Future Directions 

Findings of early sleep differences in infants with DS suggest opportunities for early intervention before age 1 year. Current clinical trials are evaluating oxygen therapy and home sleep testing as alternatives to traditional PSG. Researchers are also examining long-term benefits of HGNS in improving neurocognitive outcomes and quality of life. 

Key Takeaways for Pediatricians 

• Sleep disorders, particularly OSA, are highly prevalent in DS and often asymptomatic, requiring vigilance in primary care.
• Routine PSG by age 4 years is essential; consider earlier screening for high-risk infants and toddlers.
• Management requires a tailored, multidisciplinary approach incorporating surgical, behavioral and pharmacological strategies. 
• Emerging therapies such as HGNS devices offer hope for patients with refractory OSA. 

References:

1. Sleep & Down syndrome. National Down Syndrome Society.  https://ndss.org/sleep-down-syndrome
2. Bull MJ, Trotter T, Santoro SL, et al. Health supervision for children and adolescents with Down syndrome. Pediatrics. 2022;149(5):e2022057010. doi:10.1542/peds.2022-057010 
3. Sen C, Orak Ö, Günsay T, Sönmez S. Safety of adenotonsillectomy in children with genetic syndromes. Ear Nose Throat J. 2025;104(11):924-930. doi:10.1177/01455613251392448
4. Seither K, Helm BM, Heubi C, Swarr D, Suhrie KR. Sleep apnea in children with Down syndrome. Pediatrics. 2023;151(3):e2022058771. doi:10.1542/peds.2022-058771
5. Hartnick CJ, Skotko BG. Hypoglossal nerve stimulation for pediatric Down syndrome patients with OSA. Pediatrics. 2024;143(4):e2023056789. doi:10.1542/peds.2023-056789